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On the verge of entering the post-antibiotic era, numerous efforts are in place to regain
the losing potential of antibiotics which are proving ineffective against common
bacterial infections. Engineered nanomaterials, especially gold nanoparticles (GNPs)
capped with antibacterial agents are proving to be an effective and novel strategy against
multi-drug resistant (MDR) bacteria. In this study, we report a one-step synthesis of
kanamycin-capped GNPs (20 ± 5 nm) utilizing the combined reducing and capping
ability of the aminoglycoside antibiotic, kanamycin. Antibacterial assays showed dosedependent broad spectrum activity of Kan-GNPs against Gram-positive (Staphylococcus
epidermidis and Enterococcus durans), Gram-negative (Escherichia coli and
Enterobacter aerogenes) and Kan-resistant and MDR bacterial strains. A significant
reduction in the minimum inhibitory concentration (MIC) of Kan-GNPs was observed as
compared to free kanamycin against all the sensitive and resistant bacterial strains
tested. Mechanistic studies using TEM and fluorescence microscopy showed that KanGNPs exerted their bactericidal action through disrupting the cellular membrane
resulting in leakage of cytoplasmic content and death of bacterial cells. Results of this
study provide a novel method in the development of antibiotic capped GNPs as potent
next-generation antibacterial agents.

xii

1. INTRODUCTION
Bacteria belong to microorganisms which are part of earliest form of life existing
on earth. There was a time when we humans were unaware of existance of tiny
microorganisms. However, due to advancement in the field of microscopic and
instrumental techniques we were able to provide proof that these tiny micrometer size
organisms do exists and they are the causative agents for variety of diseases which were
the ultimate cause of death in primitive days. Furthermore, researchers came up with
more details regarding types of bacteria, their size and shapes, how they multiply and
what their role is in life. It has been reported that there are at least 6 billion bacteria’s
that reside on human body, but not all are pathogenic.1 With time, scientists started
understanding how bacteria cause disease in a more sophisticated way and regarded
pathogenic bacteria as “invisible enemies”.2
The first antibiotic: penicillin was discovered in 19283 by Sir Alexander Fleming
while he was studying and sorting culture of staphylococcus bacteria. During his
research, he found an unexpected growth of colonies in one of his petri plates which he
further identified as growth of mold of strain Penicillium notatum. He later had an idea
that this mold is responsible for secretion of some unknown substance which inhibited
the growth of bacteria. By the splendid discovery of antibiotic, every individual gained a
ray of hope that “Yes! now we can treat bacterial infections and live longer!” With
increase in other common infections and subsequent discovery of new generations of
available antibiotics or new classes of antibiotics, the faith in modern medicine persisted
and people enjoyed novelty of medicine. Hence, antibiotics were more commonly called
as “Wonder drugs/Miracle drugs”.4
1

Since the serendipitous discovery of the penicillin3, the process of developing
resistance against antibiotics had been initiated in bacteria which was clearly evident
from the presence of resistant bacterial strains in the early 1930's and 1940's.5,6 The
reason behind bacterial resistance to the effect of antibiotic is attributed to mechanisms
acquired or developed by bacteria such as “inactivation of drug by enzymes, alteration
of drug target, activation of drug efflux pump and inhibition of drug uptake” etc.7 These
resistant bacterial genes transfer from one generation to other and spread globally.
Antibiotic resistance was also exaggerated by other contributing factors such as
widespread use of antibiotics for livestock production, over the counter use for human
consumption, improper diagnosis, leading to prescription of antibiotics in viral
infections and dry new antibiotic pipeline, etc.5–8
The bacterial resistance has increased from single infection to range of infections
caused by bacteria, resulting in emergence of multi-drug resistant (MDR) bacterial
strains more prevalently known as "superbugs".8–13 Common examples of such
infections includes methicillin-resistant Staphylococcus aureus (MRSA), carbapenamresistant enterobacteriaceae (CRE), extended spectrum β-lactamase producing
enterobacteriaceae (ESBLs), etc.14,15 Most of these infections are hospital acquired
infections.16 According to World Health Organization (WHO), out of every 100 inpatients, at least 7 patients in high-income and at least 10 patients in low-/middle income
countries may acquire a hospital acquired infection.17 The rate at which bacteria are
becoming resistant to existing antibiotics is faster than the development of novel
antibiotics.18,19 This bacterial resistance threatens the achievements of modern medicine,
2

such as organ transplantation, and common surgeries which are at higher risks of postoperative infections.14,18,19
According to the recent report by Centers for Disease Control and Prevention
(CDC), more than 23,000 people die annually from resistant bacterial infections in the
United States.15 Hence, dominance of antibiotics are superseded by bacteria and we are
failing to treat common bacterial infections. This current situation can be summed up in
a single phrase where we are able to counteract big wars, but we are losing war to these
tiny bugs.4 Therefore, it requires an urgent call to curb ill effects of MDR bacteria and
prevent it from becoming pan-drug resistant (PDR) bacteria i.e., bacteria becoming
resistant to all available antibiotics.14,15
Several strategies are being employed to develop novel antibacterial agents.
Aware of the exorbitant cost and time required to conduct research, scale up production,
validate a process, and get an approval from regulatory bodies leading to success in a
new chemical entity into the market, the current focus is shifting from developing new
antibiotics to potentiating the activity of commercially successful antibiotics using
alternative methods.20 Nanotechnology is one of the alternative route which is been
under study for biological applications. It involves nanoparticles which deals with
particles in size range of one billionth of a meter (1-100 nm).21 Nanoparticles possess
unique optical properties when compared to bulk particles.21,22 They have been studied
for

various

applications

such

diagnosis,23

as

biosensors,24

catalysis,25

photothermolysis,26 drug delivery27 and gene therapy (Figure 1).28 Various researchers
have reported successful capping of biomolecules on GNPs with similar or modified
3

pharmacological activity compared to bulk drug. For example, Gu et al have reported
multiple fold in vivo potency for vancomycin-GNPs against vancomycin resistant
enterobacteriaceae.29

Abraxane®

(paclitaxel-albumin

stabilized

nanoparticle

formulation) has been approved by USFDA in September 2013.30 Till date, no safety
concern has been reported for the drugs in nano scale range.31

4

Figure 1. Illustrates applications of gold nanoparticles. Gold nanoparticles are being
studied for variety of applications such as diagnosis, biosensors, catalysis,
photothermolysis, drug delivery and gene therapy.
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One of the widely researched strategies involves use of metallic and metal oxide
nanoparticles (1-100 nm) such as gold (Au), silver (Ag), zinc oxide (ZnO) and many
more for their synergistic role in enhanced bactericidal activity.32,33 Among various
inorganic nanomaterials, gold nanoparticles (GNPs) have gained immense attention in
designing and developing new biomedical applications.21,22,34 Recently, ultra-fine, nontoxic GNPs are also being widely studied for combating endemic MDR bacteria.29,33,34
Some of the inherent features of GNPs such as biosafety,35,36 ease of functionalization,37
facile synthesis,22,38,39 and large surface/volume ratio allowing the release of high drug
payload at the infected sites.40 GNPs also provides multiple-targets of bactericidal
action, ability to penetrate biological membranes20,40 and many other relevant features
that make GNPs the preferred candidates for developing novel antibacterial agents.
Unlike the wide use of nanoparticles for cancer therapy,41–43 less extensive efforts have
been made in the field of antibacterial agents as evident from a lack of FDA approved
antibacterial formulation based on nanotechnology.33 Common methods that are
employed for making GNPs involve multi-stepped use of organic chemicals and harsh
reaction conditions, which could have detrimental effects on biological systems.44–49
As an alternative route to prepare novel antibacterial nanoformulation by capping
antibiotic onto GNPs in biofriendly manner, we selected kanamycin antibiotic.
Kanamycin sulfate, derived from Streptomyces kanamyceticus, is a broad spectrum
aminoglycoside antibiotic discovered in 1956.50 Kanamycin is also classified under
essential medicine list by WHO.51 Kanamycin is used in treatment of infections caused
by pathogens such as E. coli, Proteus species (both indole-positive and indole-negative),
6

Enterobacter

aerogenes,

Klebsiella

pneumoniae,

Serratia

marcescens,

and

Acinetobacter species.52–54 These organisms belong to a class of “ESKAPE” organisms
which are primary cause for hospital acquired infections in U.S.55 Kanamycin acts by
binding onto the 30S ribosomal subunit in prokaryotes thereby inhibiting protein
synthesis.52,56 Bacteria have developed resistance to the antibacterial effects of
kanamycin, thereby limiting its use in therapy.52
We took an approach to develop antibiotic capped gold nanoparticles for potent
antibacterial activity to curb the ill effects of resistant bacteria. Extending the scope of a
method57,58 we developed to efficiently generate biomolecules capped-GNPs, in this
study we report a simple kanamycin-mediated, bio-friendly synthesis and concomitant
capping of GNPs, resulting in enhanced broad-spectrum antibacterial activity.
In this study, we synthesized Kan-GNPs and optimized its synthesis process. The
synthesized Kan-GNPs were morphologically characterized using transmission electron
microscopy (TEM), scanning electron microscopy, energy dispersive spectroscopy, UVVis spectroscopy, thermo gravimetric analysis, zeta potential and dynamic light
scattering. Furthermore, Kan-GNPs were evaluated for their antibacterial efficiency
against Gram positive, Gram negative, kanamycin sensitive, kanamycin resistant and
multi-drug resistant (MDR) bacterial strains. Using TEM, we visualized morphological
changes occurring in bacteria upon treating with minimum inhibitory concentration
(MIC) concentration of Kan-GNPs. Our results demonstrate the successful development
of a highly efficient Kan-GNPs against several infectious bacterial strains, suggesting a
novel strategy to combat MDR bacteria.
7

2. MATERIALS AND METHODS
2.1. Materials

Formvar 15/95 resin, powder
Glycerol
Kanamycin sulfate
L.B agar media
L.B media

Catalog
Number
63450-15-7
GX0190-6
80058-286
240110
71753-6

Electron Microscopy Sciences
EMD Chemicals
Calbiochem
BD Company
Novagen

Menadione

ME105

Spectrum Chemicals

Potassium aurochlorate
Potassium phosphate, dibasic (K2HPO4)
Potassium phosphate, monobasic
(KH2PO4)
Potassium sulphate
Propidium iodide
Sodium chloride
Sodium phosphate, dibasic, 12-Hydrate
T.S agar media
T.S media
XTT salt

450235
PX1570-1

Sigma Aldrich
EMD Chemicals

PX1565-5

EMD Chemicals

PX1595-1
537059
3624-05
SX0718-1
236950
T0420
10060

EMD Chemicals
Calbiochem
J.T. Baker
EMD Chemicals
BD Company
Teknova
Biotium

Chemicals

Vendor

Table 1. Represents list of all the chemicals used for the research project with catalog
number and vendor details respectively.
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2.2. Supplies
Catalog
Number

Supply material
96 well Flat Bottom, Non-Treated, Sterile,
Polystyrene, Microtiter Plates
Microcentrifuge Tubes – 1.5 mL
Falcon Tubes – 15 mL
Falcon Tubes – 50 mL
Glass Culture tubes
Micropipette Tips (1-20 µL)
Micropipette Tips (1-200 µL)
Micropipette Tips (1-1000 µL)
Nalgene™ Oakridge High speed PPCO
centrifuge tubes
Sterile Polystyrene Petri Dish
(100 mm x 15mm)
TEM grids
(400 square mesh, Oval Hole)

Vendor

25381-056

Costar

87003-294
89039-666
89004-364
14-961-27
53509-070
53503-606
83007-382

VWR
VWR
VWR
Fisher brand
VWR
VWR
VWR

3119-0030

Thermo Scientific

875713

Fisher Scientific

G400-Cu

Electron Microscopy
Sciences

Table 2. Represents list of supply material used with catalog number and vendor details
respectively.
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2.3. Equipments
Equipment’s
Autoclave Machine, GETINGE

Use
Sterilize solutions and supplies
Concentrate gold nanoparticles
Centrific centrifuge (Model 228)
(Medium scale)
Concentrate gold nanoparticles
Eppendorf Centrifuge
(Small scale)
Excella E25 Incubator Shaker
Bacterial and nanoparticle incubation
-80 °C Freezer, Thermo scientific
Store bacterial stock culture
Optical absorption of nanoparticle
Hitachi U-3900 Spectrophotometer
solution
Morphological characterization of
JEOL JEM-1400 Plus Electron Microscope
kanamycin gold nanoparticles
Elemental composition of
JEOL JSM-5400 LV Scanning Microscope
nanoparticles
Thermo scientific Bath Circulator (Haake A25, Temperature dependent synthesis of
Haake SC150)
nanoparticles
LABONCO Biological Safety Cabinet, Logic,
Working with bacteria
Class II, Type A2
(aseptic conditions)
LABONCO Centrivap Cold Trap Lyophlizer
Freeze-drying of gold nanoparticles
METTLER TOLEDO New Classic MF Balance Weighing of raw materials,
(Model: ML 54/03)
nanoparticles etc.
MISONIX ultrasonic Liquid Processor XL-2000 Break the aggregation of
Probe Sonicator (Model: CML-4)
nanoparticles
NANOpure infinity, Ultrapure water system,
Nano pure water (17.8-18.3 mΩ-cm)
Barnstead water machine
Petri Plate Scanner
Counting colonies on petri plates
Refrigerator
Storing the solutions and reagents
SPECTRONIC 20D+ Thermo Spectronic
To check optical density of bacteria
Concentrate gold nanoparticles
Sorval RC-5B/5C Plus centrifuge
(Large scale synthesis)
Synergy H1 Hybrid Plate reader, Biotek
Bacterial growth assay
Organic percent determination on
TA Thermogravimetric Analysis, Q5000
gold nanoparticles
VWR Incubator
Growth of bacteria on agar plates
Zetasizer Nano S (Malvern Instruments Ltd.)
Particle size distribution
Table 3. Represents list of equipment’s used, their make and uses respectively.
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2.4. Bacterial strains used for investigation
Bacterial Strains

Gram Bacteria Type

Staphylococcus epidermidis

Gram positive

Enterococcus durans
Enterobacter aerogenes
Escherichia coli
Yersinia pestis CO92
Yersinia pestis CO92::Km
Pseudomonas aeruginosa PA01
Pseudomonas aeruginosa UNC-D-1

Gram negative

ATCC #
12228
6056
13048
67877

Kanamycin resistant bacteria
__
Multi-drug resistant bacteria

Table 4. List of Gram positive, Gram negative, kanamycin resistant and multidrug
resistant bacterial strains used in the research project.
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2.5. Preparation of reagents
2.5.1. Cleaning protocol
All the glassware/apparatus/containers were thoroughly rinsed and washed with
soap water followed by tap water and nanopure water and allowed to air dry.
Furthermore, the apparatus were subjected to dry heat sterilization before use.
2.5.2. Preparation of sterile nanopure water
500 mL of nanopure water was collected in a sterile 1000 mL glass bottle. The cap
was screwed loosely and the nanopure water was sterilized by moist heat sterilization
using an autoclave.
2.5.3. Preparation of minimal media [M9 media without NH4Cl] (1L, pH 7.2 ± 0.2)
Following cleaning protocol, a 1 L Erlenmeyer flask, two 1 L glass bottles, a 1 L
graduated cylinder, a magnetic stirrer and a spatula was obtained. 13 g potassium
phosphate, monobasic (KH2PO4), 10 g potassium phosphate, dibasic (K2HPO4), 9 g
sodium phosphate, dibasic, 12-Hydrate (Na2HPO4), and 2.4 g potassium sulphate
(K2SO4) were weighed accurately and transfered it to the 1 L Erlenmeyer flask.
Approximately 800 mL of nanopure water was added to the Erlenmeyer flask. The
contents of the Erlenmeyer flask were mixed to dissolve completely using a magnetic
stirrer. In a large graduated cylinder, the volume was made up to 1000 mL using
autoclaved nano pure water. 500 mL of solution was transferred to each 1 liter glass
bottles. The bottles cap were screwed loosely and were sterilized by moist heat
sterilization using an autoclave.
12

2.5.4. Preparation of kanamycin sulfate stock solution: (1.72 mM, 30 mL)
𝑀𝑜𝑙𝑎𝑟𝑖𝑡𝑦 =

𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑘𝑎𝑛𝑎𝑚𝑦𝑐𝑖𝑛 (𝑔)
1000 𝑚𝐿
𝑋
𝑀𝑜𝑙𝑒𝑐𝑢𝑙𝑎𝑟 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑘𝑎𝑛𝑎𝑚𝑦𝑐𝑖𝑛
𝑉 𝑖𝑛 𝑚𝐿

𝑀𝑜𝑙𝑒𝑐𝑢𝑙𝑎𝑟 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑘𝑎𝑛𝑎𝑚𝑦𝑐𝑖𝑛 = 582.6

𝑔
𝑚𝑜𝑙𝑒

30 mg of kanamycin sulfate (see Appendix A for product specification) was
weighed using microbalance and transferred to 50 mL falcon tube. 30 mL of M9 media
(without NH4Cl) was added to the falcon tube. The falcon tube was thoroughly vortexed
in order to mix and dissolve the drug and a clear solution was obtained. 5 mL of drug
solution was then transferred to six different 15 mL falcon tubes.
2.5.5. Preparation of potassium gold (III) chloride stock solution (KAuCl4) (0.79
mM, 5.0 mL)
𝑀𝑜𝑙𝑎𝑟𝑖𝑡𝑦 =

𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑔𝑜𝑙𝑑 𝑠𝑎𝑙𝑡 (𝑔)
1000 𝑚𝐿
𝑋
𝑀𝑜𝑙𝑒𝑐𝑢𝑙𝑎𝑟 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑔𝑜𝑙𝑑 𝑠𝑎𝑙𝑡
𝑉 𝑖𝑛 𝑚𝐿

𝑀𝑜𝑙𝑒𝑐𝑢𝑙𝑎𝑟 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑔𝑜𝑙𝑑 𝑠𝑎𝑙𝑡 = 377.8

𝑔
𝑚𝑜𝑙𝑒

250 mg of gold salt was weighed and transferred to 15 mL Falcon tube. 5 mL of
sterile nanopure water was added to it. The mixture was vortexed to dissolve solute until
clear, homogenous yellow solution was obtained. The falcon tube was covered with
aluminum foil to protect from light. The tube was further stored at 2-8 °C in a
refrigerator until further use.
2.5.6. Preparation of Luria-Bertani media (LB) (1L)
Following the cleaning protocol, 25 g of L.B media was weighed accurately and
transferred to 2 L Erlenmeyer flask. Approximately 800 mL of autoclaved nanopure
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water was added to it. The L.B media was completely mixed and dissolved in nanopure
water using a magnetic stirrer. The volume was made up to 1000 mL using autoclaved
nanopure water in a graduated cylinder. The resulting solution was then further
transferred equally into two glass bottles (1 L capacity) and sterilized using autoclave.
The solution was further stored in a refrigerator between 2-8 °C until further use.
Note: It is highly recommended to prepare fresh stock every time before use.
2.5.7. Preparation of Tryptic-Soy media (T.S) (1L)
Following the cleaning protocol, 30 g of T.S media was weighed accurately and
transferred to 2 L Erlenmeyer flask. Approximately 800 mL of autoclaved nanopure
water was added to it. The T.S media was completely mixed and dissolved in nanopure
water using magnetic stirrer. The volume was made up to 1000 mL with nanopure water
using a graduated measuring cylinder. The resulting solution was then further transferred
equally into two glass bottles (1L capacity) and sterilized using autoclave. The solution
was further stored in a refrigerator at 2-8 °C until further use.
2.5.8. Preparation of L.B/T.S agar plates
Following the cleaning protocol, 40 g of L.B agar/T.S agar was weighed and
transferred into a 2 L Erlenmeyer flask. Approximately 800 mL of autoclaved nanopure
water was added to it. The agar media was completely mixed and dissolved in nanopure
water using a magnetic stirrer. The volume was made up to 1000 mL in a graduated
cylinder using autoclaved nanopure water. The flask was then covered with double
folded aluminum foil and sterilized using moist heat sterilization. In the meantime,
polystyrene petridishes were obtained and sterilized using UV light in a biological safety
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cabinet. After sterilization of agar media, the flask was allowed to sit for pproximately 5
minutes. 25 mL of sterilized media was poured in each petri dish using 50 mL falcon
tube. At room temperature, the plates were allowed to solidify in biological safety
cabinet by covering half portion of cap open. After solidification, the plates were
wrapped using parafilm around its circumference, labeled and stored in refrigerator
between 2-8 °C for further use. Note: The solidification of agar takes place at
approximately 35 °C. Hence, care should be taken after autoclave for not allowing flask
to sit for longer time.
2.5.9. Preparation of 10X phosphate buffer saline (PBS) (1L, pH 7.2 ± 0.2)
Following the cleaning protocol, 5.519 g sodium dihydrogen phosphate, 42.89 g
disodium hydrogen phosphate and 87.66 g sodium chloride were weighed and
transferred it to 2 L Erlenmeyer flask. Approximately 800 mL of autoclaved nanopure
water was added and the solutes were mixed to dissolve. The volume was made up to
1000 mL in a graduated measuring cylinder using autoclaved nanopure water. The pH of
solution was adjusted to pH 7.2 using calibrated pH meter. The 500 mL of solution was
transferred to two reagent bottles, screw capped loosely and subjected to moist heat
sterilization. After sterilization, the bottles were labeled, screw capped tightly and stored
at room temperature until further use.
2.5.10. Preparation of 1X phosphate buffer saline (PBS) (0.5L, pH 7.2 ± 0.2)
Following the cleaning protocol, 50 mL of 10X PBS was diluted to 500 mL
using autoclaved nanopure water in a graduated cylinder. The pH of solution was
adjusted to pH 7.2 using calibrated pH meter. This solution was then transferred to 1 L
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reagent bottle, screw capped loosely and subjected to moist heat sterilization. After
sterilization, the bottles were labeled, screw capped tightly and stored at room
temperature until further use.
2.5.11. Preparation of tetrazolium salt solution (XTT) (30 mL)
Following the cleaning protocol, 30 mg of XTT dye was weighed and transferred
to 100 cc Erlenmeyer flask containing 30 mL of phosphate buffer saline (1X PBS, pH
7.2). The flask was covered with double folded aluminum foil (protected from light) and
sterilized using moist heat sterilization method. After sterilization, 995 µL of XTT
solution was aliquot (under aseptic conditions) into 1.5 mL eppendorf centrifuge tubes,
labelled and stored at -4 °C freezer until further use.
2.5.12. Preparation of menadione solution (10 mM, 50 mL)
𝑀𝑜𝑙𝑎𝑟𝑖𝑡𝑦 =

𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑚𝑒𝑛𝑎𝑑𝑖𝑜𝑛𝑒 (𝑔)
1000 𝑚𝐿
𝑋
𝑀𝑜𝑙𝑒𝑐𝑢𝑙𝑎𝑟 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑚𝑒𝑛𝑎𝑑𝑖𝑜𝑛𝑒
𝑉 𝑖𝑛 𝑚𝐿

𝑀𝑜𝑙𝑒𝑐𝑢𝑙𝑎𝑟 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑚𝑒𝑛𝑎𝑑𝑖𝑜𝑛𝑒 = 172.18

𝑔
𝑚𝑜𝑙𝑒

Following cleaning protocol, 86 mg of menadione was weighed accurately and
dissolved in 50 mL acetone in a 100 mL glass bottle. The bottle was labelled and stored
in a refrigerator at -4 °C for further use.
2.5.13. Preparation of 1 % formvar solution
Prepare a 1 % solution of formvar by dissolving 1 gram polyvinyl formvar
desiccated resin powder in 100 mL ethylene dichloride solvent. Keep the reaction
mixture overnight in order to completely dissolve resin in solvent.
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2.5.14. Preparation of TEM grids
A 400 square mesh, oval hole copper grids were obtained and washed in 1 M HCl
solution in order to remove any dust particles followed by air drying. The grids were
further washed in water and air dryed. A final wash with acetone followed by air drying
was done for copper grids. The burette apparatus was set up and formvar coating
solution was added into burette. A clean glass slide was dipped into the burette holding
formvar solution and kept in contact for approximately 30 seconds. The glass slide was
removed using tweezer and air dried. A surgical grade blade was used to scrap the edges
of the glass slide. This process technically provides different films on each side of glass
slide. The film coating was then further removed from glass slide by immersing it into a
glass jar completely filled with distilled water. The formvar film so obtained was
deposited onto light side of washed copper grids by holding copper grids inversely (light
side facing downwards) and placing it onto formvar film at surface of water. Parafilm
was used to obtain formvar film containing copper grids. The copper grids (with formvar
film on top) were then removed from parafilm using sharp tweezer and kept separately
in a petri plate containing a filter paper.
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2.6. Experimental Methods
2.6.1. Synthesis of Kanamycin gold nanoparticles (Kan-GNPs)
Kan-GNPs was synthesized in a single step process (Figure 2) which involves a
reaction of kanamycin drug in an aqueous buffer with an aqueous solution of KAuCl4.
Aiming at making monodisperse and stable Kan-GNPs with a uniform particle size, we
carried out reactions at different concentrations of each reaction components. The
combination which yielded desired morphology of Kan-GNPs with high percentage
yield was selected. For a typical synthesis, 1.72 mM of kanamycin was dissolved in
aqueous buffer (pH ~7.2 ± 0.2) and was preheated above room temperature.
Furthermore, 0.79 mM of KAuCl4 (30 µL from 50 mg/mL solution) was added and
reaction mixture was incubated for 5 minutes. After incubation, the reaction tubes were
removed and cooled at room temperature. The formation of Kan-GNPs was confirmed
by visual change of a reaction mixture from colorless to pink. The Kan-GNPs
suspension was then subject to repeated washing with autoclaved nanopure water and
centrifugation (15,000 rpm for 20 minutes) to remove any traces of free reactants
remaining in the reaction mixture. Sterile oakridge tubes were used for centrifugation in
Sorval RC 5B/5C Plus Centrifuge set with F21 rotor. Supernatant solution was discarded
at each centrifugation step and replaced with autoclaved nanopure water for further
washing. The concentrated Kan-GNPs suspension was then obtained after final washing
and purification procedure, freeze-dried and stored at room temperature for further
analysis.
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Figure 2. Illustrates a single step scheme for Kan-GNPs synthesis. In this process,
kanamycin itself acts as reducing and capping agent.
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2.6.2. Freeze-drying of synthesized Kan-GNPs
Freeze-drying of Kan-GNPs had various advantages such as ease in storage,
weighing and handling and convenience in determining the dose of Kan-GNPs to be
selected for further antibacterial testing. This also indicates robustness of manufacturing
process with respect to percentage yields. For freeze-drying process, Kan-GNPs (100
mL batch) was synthesized, washed, centrifuged, and concentrated to a final volume of 2
mL in nanopure water. The LABONCO Centrivap Cold Trap Lyophlizer was switched
on 2 hours prior to freeze-drying to attain - 30 °C temperature. Concentrated Kan-GNPs
suspension was then transferred to two different stainless steel cups, freezed in liquid
nitrogen, and covered with miracloth which allowes loss of moisture but not permeable
for loss of nanomaterials. The cups were then readily transferred to lyophilization
chamber (previously cooled and maintained at -30 °C). The chamber was closed and
vacuum was switched on. The samples specimen were kept overnight under freezing
conditions. Temperature variation was performed the following day with increasing
temperature by 5 °C at specific time interval. At 30 °C, the lyophlizer was switched off
and the dried Kan-GNPs were collected, weighed accurately and stored in a glass vial at
room temperature for further analysis.
2.6.3. Characterization of Kan-GNPs
Though synthesis of Kan-GNPs was physically noted by change in color of the
reaction mixture, still it is very important to determine if kanamycin is actually capped
onto gold nanoparticle surface. Thus, various electron microscopic and spectroscopic
techniques were used to confirm presence of antibiotic kanamycin on GNPs surfaces.
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UV-Vis spectroscopy (UV-Vis)
Gold nanoparticles possess a characteristic optical property, called surface
plasmon resonance (SPR).59 This SPR band is observed in visible range of light and it
depends on the size of particles, shape of particles and chemical environment in which
nanoparticles (NPs) are present. Hence, UV-Vis spectroscopy was used as a qualitative
analytical spectrometric technique to confirm the formation of Kan-GNPs. A dilute
suspension of Kan-GNPs was probe sonicated for 30 seconds at 45 % amplitude. UVVis absorption spectrum of resulting suspension was recorded in the wavelength range
of 400-850 nm using a Hitachi U-3900 spectrophotometer at a resolution of 0.5 nm and
scanning speed of 600 nm/min while maintaining slit width at set value of 5 nm and path
length 10 mm.
Dynamic light scattering (DLS)
DLS is a rapid and accurate technique used to characterize nanoparticles
suspended in liquid medium.60 Diameter and average particle size distribution of
synthesized Kan-GNPs were determined using a Zetasizer Nano S (Malvern Instruments
Ltd.). The motion of nanoparticles in suspension leads to scattering of laser light at
different intensity, causing intensity fluctuations, which is further recorded and
analyzed, and particle velocity was determined. To analyze Kan-GNPs, dilute
suspension of Kan-GNPs was probe-sonicated for 30 seconds at 45 % amplitude. The
average of three individual measurements in total of 13 runs was recorded in 1 mL of
sample. The data so obtained was plotted and average particle size distribution along
with polydispersity was determined.
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Transmission electron microscopy (TEM)
Transmission electron microscope possesses high image resolution at nanometer
range.58 It works based on the principle of interaction of beam of an electron with a thin
specimen sample, thus transmitted electrons produce an image of sample on phosphorus
screen and the size and shape of nanoparticles were determined. To analyze Kan-GNPs,
a dilute suspension of Kan-GNPs was probe sonicated for 30 seconds at 45 % amplitude.
10 µL of above suspension was loaded onto 400 square mesh, oval hole formvar coated
copper grid and was allowed to air dry before observing under JEOL JEM-1400 Plus
transmission electron microscope. The sample was allowed to be in contact with
formvar film on grid. Excess sample was wiped off using filter paper wedge. The beam
of an electron was maintained at 100 kv electron voltage and the image of desired region
was taken at different magnifications using a built-in camera. The scale bar of the
respective size of an image automatically was included in image based on magnification
value.
Scanning electron microscopy-energy dispersive spectroscopy (SEM-EDS)
Surface morphology of Kan-GNPs was studied using scanning electron
microscopy (SEM) and elemental compositions including a gold and carbon was
detected by high sensitive energy dispersive X-Ray spectroscopy (EDS) using a JEOL
JSM-5400 LV with IXRF system. For a typical analysis, 50 µL of Kan-GNPs
suspension (previously probe sonicated) was pipetted on rough side of clean silicon
chip. The silicon chip containing sample was spin coated and placed in a petri plate and
further dried under vacuum chamber for approximately 2 hours. The silicon chip was
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then imaged onto SEM and elemental composition was determined using EDS. The
SEM images were then exported into a built-in software and elemental composition of
Kan-GNPs was determined at different sampling spots using IXRF system. The presence
of organic compound was confirmed onto GNPs surface and the elements and their
respective percent weights were then detected.
Thermogravimetric analysis (TGA)
Thermal analysis is an important quantitative method to determine amount of
organic content capped on GNPs surface.61 To determine how much kanamycin is
coated on GNPs, 5-10 mg of freeze dried powder of Kan-GNPs was placed in a platinum
pan which was supported by a highly precise balance. The pan was introduced into
furnace chamber in Q5000 TGA and subjected to thermal decomposition from room
temperature till 850 °C. The sample environment is governed by sample purge gas used.
Two types of methods (i.e., using nitrogen and air as purge gas) were employed to study
the thermal degradation of Kan-GNPs (Appendix B: Method). In method I, Kan-GNPs
were thermally degraded in inert conditions using nitrogen as purge gas till 650 °C
followed by air till 850 °C to facilitate complete degradation of the organic content. In
method II, air was used as a purge gas right from room temperature to 850 °C to
facilitate complete oxidation of kanamycin. The weight loss of Kan-GNPs was
monitored as a function of temperature throughout the experiment. A thermogram with
percent weight on Y-axis and temperature on X-axis was plotted using universal TA
software and thermal degradation pattern of kanamycin was studied. The thermal
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analysis experiment of Kan-GNPs was repeated three times to confirm the percent
weight of kanamycin on GNPs surface.
Zeta potential
Zeta potential provides a net electrical charge at the interface in colloidal
system.62 For nanoparticles suspension, measuring charge of GNPs is a very key
parameter for predicting its stability. It is also reported that negatively charged bacterial
cell membrane attracts positively charged nanoparticles, thereby contributing to the
bactericidal action of GNPs. Kan-GNPs were analyzed for zeta potential using Zetasizer
Nano S (Malvern Instruments Ltd.) equipment. Kan-GNPs showed positive charge of
+23.4 mV.
2.6.4. Evaluation of antibacterial activity of Kan-GNPs
Kan-GNPs were tested for in vitro antibacterial activity against Gram-positive
(Staphylococcus epidermidis and Enterococcus durans), Gram-negative (Escherichia
coli and Enterobacter aerogenes), kanamycin resistant (Y. pestis C092::km) and multidrug resistance (P. aeruginosa UNC D-1) bacterial strains.
Preparation of glycerol stock of bacterial strains
A fresh glycerol stock of desired bacterial strains were prepared in respective
nutrient media when required. A preculture of desired bacterial strain was grown by
adding 200 µL of bacterial stock in 10 mL of respective nutrient media (L.B/T.S) in a 50
mL UV sterilized falcon tube. The bacterial suspension was mixed and incubated
overnight in a incubator shaker at 37 °C, 150 rpm for 12-20 hours. After incubation
interval, the growth of bacteria was determined by measuring the optical density (O.D)
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of bacterial culture at 600 nm using 4 mL of culture in a clean sterilized glass testube in
Spectronic-20 spectrometer corrected with a blank. When the O.D of bacterial culture
reached to a value of ~1.2, a 1.5 mL (10 %) of glycerol was added to the bacterial
culture in falcon tube and mixed thoroughly. 250 µL of resulting suspension was aliquot
into 1.5 mL sterilized labelled eppendorf centrifuge tubes. The culture containing tubes
immediately kept in contact with liquid nitrogen and freezed. After all the tubes were
completed for preparing an aliquot, the culture containing tubes were transferred to – 80
°C freezer until further use. The entire process of preparing a glycerol stock was
conducted in biological safety cabinet in the presence of blue flame using bunsen burner
to ensure aseptic conditions.
Preparation of preculture of bacterial strains
A preculture of desired bacterial strain was prepared by thawing the glycerol
stock of respective bacterial strain. 10 mL of nutrient media (L.B/T.S) was added into 50
mL UV sterilized falcon tube. 200 µL of thawed bacterial suspension from glycerol
stock was transferred into falcon tube. The sample was mixed properly and then
incubated overnight at 37 °C, 150 rpm for ~12-20 hours. The growth of bacteria was
determined by testing O.D of bacterial culture. The desired O.D for testing is ~1.2.
Table 5 represents the preculture conditions for each bacterial strain used for
antibacterial assay.

25

Bacterial Strain
Staphylococcus epidermidis
Enterococcus durans
Enterobacter aerogenes
Escherichia coli

Gram
Bacteria
Type

Nutrient Media
Type
L.B/T.S Broth

Gram
positive

T.S Broth
L.B Broth

Gram
negative

L.B/T.S Broth

Incubation
Time &
Conditions
37 °C, 150 rpm,
12-14 hrs
37 °C, 150 rpm,
18-20 hrs
37 °C, 150 rpm,
12-14 hrs
37 °C, 150 rpm,
12-14 hrs

Table 5. Represents incubation time and conditions for preparing small scale preculture
of various Gram positive and Gram negative bacterial strains tested.

In-vitro antibacterial assay
In-vitro antibacterial activity of Kan-GNPs were tested on the basis of dose
against Gram-positive (Staphylococcus epidermidis and Enterococcus durans), and
Gram-negative (Escherichia coli and Enterobacter aerogenes) bacteria at Dr.
Rajalingam Dakshinamurthy`s lab. The effect of Kan-GNPs against kanamycin
resistance bacteria (Y pestis CO92::km) and MDR bacteria (P. aeruginosa UNC D-1)
were tested at the Dr. Matthew Lawrenz lab at the Center for Predictive Medicine,
University of Louisville School of Medicine. For the control, the cognate antibiotic
kanamycin (i.e., kanamycin without GNPs) was included in all studies. The minimum
inhibitory concentration (MIC) was calculated from the average MIC of three individual
experiments. The MIC values obtained were utilized to establish experimental
conditions for testing kanamycin resistant and MDR bacterial strains. The concentration
of gram bacteria was maintained uniform at 1x106 CFU per mL whereas concentration
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of 3x105 CFU per mL of bacterial suspension was used for antibacterial testing for
kanamycin resistant and MDR bacterial strains.
Bacterial growth curve assay
The bacteriostatic/bactericidal activity elucidation of Kan-GNPs was performed
to measure cell viability after exposure to Kan-GNPs nanoformulation as a function of
time.58,63 The lowest concentration of Kan-GNPs required to kill bacterial cells was
determined as MIC against the particular bacterial strain.64,65 The in vitro antibacterial
assay was performed in a 96 well microtiter plate (Appendix D). The circumference of
microtiter plate was filled with sterilized nanopure water to prevent loss of sample due
to evaporation from sample wells during incubation conditions. Each reaction plate
contained three sample rows (comprising of Kan-GNPs + nutrient media and bacterial
cells) to study the effect of Kan-GNPs on growth of bacteria, one row as positive control
(comprising nutrient media + bacterial cells) to study growth of bacteria in the absence
of Kan-GNPs and one blank row as a negative control (comprising of Kan-GNPs +
nutrient media) to subtract the absorbance for Kan-GNPs and nutrients by themselves.
A standard stock solution of Kan-GNPs (1 mg/mL) was prepared using
autoclaved nanopure water which was used to make various concentrations required for
the antibacterial study. Growth of Gram-positive (Staphylococcus epidermidis and
Enterococcus durans) and Gram-negative (Escherichia coli and Enterobacter
aerogenes) bacterial strains in the presence of Kan-GNPs was measured using a
microtiter broth method.64 Test samples contained serial dilutions of Kan-GNPs with a
final volume of 100 µL in a UV sterilized 96-well microtiter plate. 10 µL of fresh
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cultures of a bacterial strain grown overnight at 37 °C, 150 rpm were inoculated into the
sample wells. A final volume of 250 µL was achieved in each well using the respective
nutrient media. Wells containing the same concentration of Kan-GNPs (100 µL) with
150 µL of growth media were used as a negative control. For the positive growth
control, the same volume of Kan-GNPs was replaced with equal amount of nanopure
water. The plates were incubated at 37 °C, 150 rpm. Using a microtiter plate reader, the
optical density at 600 nm (OD600 nm) was measured every three hours for a period of 12
hours. A graph of O.D 600 nm was plotted against time (hrs). The same procedure was
repeated for pure kanamycin and MIC values were compared with that of Kan-GNPs.
Spread Plate Assay
In addition to the growth curve assay, solid agar plate assay was performed to
check the viable bacterial cells in the presence of different concentrations of KanGNPs.58,63 Spread plate assay was used to determine minimum bactericidal
concentrations (MBC) i.e., the lowest concentration of Kan-GNPs that kills 99.9 % of
bacteria upon treating with nanoparticles.
For this study, a respective bacterial strain was incubated in the presence and
absence (control) of Kan-GNPs for 12 hours at 37 °C and 150 rpm. Following the
incubation time, small volume of bacterial suspension samples were evenly spread onto
a fresh, nutrient L.B/T.S agar plates using sterilized glass spreader in aseptic conditions.
The plates were incubated for 12-16 hours followed by counting of viable numbers of
bacterial colonies. The procedure was performed in triplicate and the average number of
colonies from three measurements was used. The concentration which showed more
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than 90 percent reduction in number of colonies was considered as MIC concentration.
Hence, this assay was used to visibly confirm the MIC values obtained from growth
curve assay.
2,3-Bis-(2-Methoxy-4-Nitro-5-Sulfophenyl)-2H-Tetrazolium-5-Carboxanilide
(XTT) assay
XTT assay is a modern, simple, rapid, sensitive, and reliable colorimetric method
used in cell proliferation, cytotoxicity and apoptosis studies.66 XTT, a yellow
tetrazolium salt in the presence of a dehydrogenase enzyme in metabolically active cells
is reduced to bright orange formazan derivative.66 Live cells have reducing environment
due to electron transport chain mechanism (Figure 3). It measures the viable cell count
by measuring the reducing activity of cells. Optimum cell concentration and incubation
time were used based on the best suited culture conditions as observed in growth assays.
The amount of the formazan produced is proportional to viable cells present and was
quantified by measuring the absorbance at 492 nm using H1 Synergy plate reader.
To amplify the results of XTT, an activator called menadione was added.66 50 µL
of XTT tetrazolium salt stock solution containing menadione (995 µL XTT solution + 5
µL menadione) was added to the growth curve assay wells (test samples, positive and
negative control) and plate was incubated for 2 hours at 37 °C, 150 rpm in the dark,
followed by their absorbance measurement (at 0 and 2 hrs interval of adding XTT) at
492 nm. A graph of absorbance @ 492 nm against concentration of Kan-GNPs was
plotted. The concentration of Kan-GNPs which resulted in no orange color formation or
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90 % reduction in absorbance as compared to the positive control was taken as the MIC.
All the MIC measurements were done in triplicate.

Figure 3. Illustrates bacterial cell viability detection mechanism by XTT assay.
Metabolically active bacteria due to dehydrogenase enzyme reduces yellow tetrazolium
salt (XTT) to orange-red colored formazan derivative.

30

Antibacterial assay against kanamycin resistant and MDR bacteria
For Kan resistant bacteria the minimum inhibitory concentration (MIC) was
determined. Briefly, for Yersinia pestis 2-fold serially diluted Kan-GNPs concentrations
were added to wells of a clear microtiter plate. 3x105 colony forming units (CFU) were
then added and microtiter plates were incubated at 26 °C for 10 hours. Similar microtiter
plates were prepared for P. aeruginosa, and incubated at 37 °C for 10 hours
respectively. MICs were determined as Kan-GNPs concentration that completely
inhibited bacterial growth (MIC100). The average MIC100 from three independent
experiments was calculated.
2.6.5. Visualization of bactericidal action of Kan-GNPs
Cellular imaging using propidium iodide (PI) was done to determine the
antibacterial mechanism of Kan-GNPs.67 PI is a red-fluorescent dye which has high
affinity towards bacterial DNA. Due to its inability to permeate living cells, it can be
used to detect dead cells in a bacterial population.67 A respective bacterial strain was
incubated in the presence of the MIC of Kan-GNPs for ~12 hours followed by which the
samples were repeatedly washed with phosphate buffer saline (PBS) and centrifuged
(6000 rpm, 3 min). Samples were further incubated with 5 µL of PI (10 mM) for 30
minutes in the dark. After incubation, unbound PI was removed by washing the sample
with 1X PBS and 10 µL of the resulting suspension was placed on a glass slide and
covered with a cover slip. The sample was viewed using a Leica fluorescence
microscope. A sample of bacteria without Kan-GNPs was taken as control. The numbers
of permeable cells (showing red fluorescence) were counted by taking an average from
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three individual measurements and a graph was plotted in comparison to control for
respective bacterial strains.
To visualize the morphological changes in bacteria after treating with KanGNPs, cross-sections of bacteria were prepared with the aid of ultramicrotome and
observed under an transmission electron microscope (TEM).68,69 1 mL of sample
containing bacterial culture incubated (37 °C, 150 rpm, and 12 hours) in the presence of
MIC concentration of Kan-GNPs was centrifuged (4000 rpm, 3 min) and the pellet was
re-suspended in 1 mL of primary fixing solvent (16 % w/v paraformaldehyde and 10 %
w/v glutaraldehyde in 50 mM sodium cacodylate buffer (pH ~7.4)) and incubated for 2
hours. After incubation, the solution was centrifuged, washed twice with cacodylate
buffer, re-suspended in 1 mL of 1% osmium tetroxide solution (OsO4), and further
incubated for 1 hour at 25 °C for post-fixation. After fixation, the bacterial samples were
washed using sterile nanopure water. Samples were further treated with series of ethanol
concentrations (25, 50, 75, 95 and 100 % respectively). The samples were dehydrated
and further centrifuged. Spur’s epoxy resin in series of (33, 66, 95 and 100 %) was used
to infiltrate pellets for one hour. The samples were left in contact with 100 % resin
overnight. The samples were then centrifuged in BEEM® capsules, which were
solidified by heating at 70 °C for 18 hours. Using glass knives for RMC MT-X ultramicrotome, ultra-thin sections of sample were cut and stained with 2 % aqueous uranyl
acetate for 15 minutes and Reynold’s lead citrate for 3 minutes. The samples were then
imaged under JEOL-100CX TEM.
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3. RESULTS AND DISCUSSION
3.1. Synthesis and characterization of Kan-GNPs
One of the vital steps in the preparation of GNPs is the addition of chemical
agents to reduce the ionic gold atoms [Au3+] to neutral gold atoms [Au0] which tends to
result in aggregation upon reaching the saturation limit. Secondary capping agents are
further added to stabilize and restrict the size of gold aggregates into the nano-range
yielding gold nanoparticles. However, using such methods requires the need of multiple
steps to purify the product from unwanted components, thus making the overall process
highly expensive and labor intensive which limits scalability. Furthermore, due to the
biological concerns of the chemical agents used in the synthesis process, emphasis to
find biologically friendly methods for synthesizing GNPs is growing.
In this context, we developed a simple single step method for making antibiotic
functionalized GNPs. The aminoglycoside kanamycin has electron rich hydroxyl and
amine functional groups which could serve as a dual reducing and capping agent. Hence,
kanamycin antibiotic was selected as a proof of concept to synthesize antibiotic capped
GNPs. The optimum concentration of kanamycin and gold required for GNPs synthesis
was determined by assessing varying concentrations of both kanamycin and KAuCl4 at
different synthesis parameters. Based on these analyses, it was determined that 1.72 mM
of kanamycin in aqueous buffer (pH ~7.2 ± 0.2) when incubated with 0.79 mM of
KAuCl4 for 5 minutes yielded the optimal production of Kan-GNPs. The kanamycin
solution was preheated above room temperature before adding KAuCl4.
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Qualitative analysis of aggregation and morphological characteristics of KanGNPs was obtained under TEM at 100 kV showed the particles to be nearly spherical in
shape and monodispersed with an average diameter of 20 ± 5 nm (Figure 4(a)). DLS is
another widely used characterization technique for nanoparticles. DLS analysis of KanGNPs showed a sharp peak with an average size distribution of 20 ± 5 nm (Figure 4(b))
which is in agreement with TEM. A UV-Vis spectrum of Kan-GNPs recorded in the
visible region (400-850 nm) showed a peak absorption (λmax) value at 546 nm (Figure
4(c)) which is in compliance with the size of GNPs obtained from TEM.
Scannning electron microscopy coupled with energy dispersive spectroscopy was
used further to determine the surface elemental composition of Kan-GNPs. Dense
portions of the highly magnified SEM image of Kan-GNPs were selected where the
electron beam was focused to obtain the localized elemental (atoms) composition using
IXRF software. Multiple spots were selected for the analysis. Results of EDS spectral
analysis revealed the presence of elemental peaks of carbon (C) and gold (Au) at ~0.2
keV and ~2.1 keV respectively (Figure 4(d)). The percent composition of carbon and
gold was found to be 16.65 % and 66.55 %, respectively. The presence of a reduced gold
peak ensured the formation of GNPs whereas the carbon peak confirmed the presence of
the organic ligand (kanamycin) on the surface of GNPs.
Thermo gravimetric analysis of Kan-GNPs was used to quantify the amount of
organic ligand (kanamycin) bound to the surface of GNPs as well as its precent weight
which is essential in calculating the actual dose of drug for in-vivo studies. Method I
(Appendix: B) was used in inert conditions using nitrogen as purge gas from room
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temperature to 650 °C followed by air till 850 °C whereas, in method II (Appendix: C)
air was used as purge gas throughout thermal degradation in order to facilitate complete
oxidation. The weight loss for Kan-GNPs was observed to be 35 % of the total mass
(Figure 4(e)). TGA of pure kanamycin was also performed for reference as shown in
(Figure 4(e)). Zeta potential was used to determine surface charge of Kan-GNPs. KanGNPs showed zeta potential of +23.4 mV.
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Figure 4. Illustration of the morphological characterization of Kan-GNPs. (a) TEM
image showing formation of well-dispersed nearly spherical Kan-GNPs in the size range
of 20 ± 5 nm. (b) Plot showing average particle size distribution of Kan-GNPs
suspension obtained using DLS. (c) UV-Vis spectra of Kan-GNPs showing a strong
absorption peak at 546 nm which is a characteristic of spherical GNPs. (d) Energy
dispersive spectroscopy (EDS) spectra of Kan-GNPs showing the presence of elemental
peak for carbon (C) and gold (Au) at 0.2 keV and 2.1 keV, respectively. Figure in the
inset shows SEM image of spin coated sample of Kan-GNPs on silicon chip obtained at
an accelerating voltage of 20 keV with a magnification of 5kX. (e) A comparison of
thermo gravimetric (TGA) analysis showing loss of organic material for kanamycin (---) and Kan-GNPs (- - -) respectively. The samples were heated from room temperature to
650 °C at a rate of 10 °C min-1 under nitrogen flow followed by heating till 850 °C under
air.
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3.2. Kan-GNPs have antibacterial activity
We evaluated the antibacterial efficacy of Kan-GNPs against a variety of Grampositive (Staphylococcus epidermidis and Enterococcus durans) and Gram-negative
(Escherichia coli and Enterobacter aerogenes) bacterial strains by observing the
bacterial growth in the presence of different concentrations of Kan-GNPs. The MIC was
determined as the lowest concentration of Kan-GNPs which showed complete inhibition
of bacterial growth or at least 90 % reduction in the absorbance of growth at 600 nm
when compared to untreated bacteria.
Overnight culture of each bacterial strain was incubated (37 °C, 150 rpm) with
different concentrations of Kan-GNPs and their growth was observed for a period of 12
hours in a 96-well microtiter plate. To verify the broad-spectrum activity of Kan-GNPs,
antibacterial tests were performed on both Gram-positive and Gram-negative strains. A
graph was plotted for O.D600 nm against time (hrs). In general, dose-dependent inhibition
of bacterial growth was observed for all bacterial strains. From the above assay MIC of
24.46 µg mL-1 and 35.23 µg mL-1 (Kan-GNPs) was observed against Gram-positive
strains S. epidermidis and E. durans respectively (Table 6). Results for the Gramnegative strains E. aerogenes and E. coli were found to be 21.82 µg mL-1 and 25.06 µg
mL-1, respectively. The MIC value observed in the bacterial growth assay was consistent
with the spread plate assay as no visible growth of bacterial colonies were observed in
presence of the Kan-GNPs at MIC (Figure 5).
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Figure 5. Illustrates dose dependent inhibition of bacterial growth by Kan-GNPs against
Gram positive, S. epidermidis (a, b) and Gram negative E. aerogenes (c, d) bacteria. (a
and c) Monitoring growth in the presence of increasing concentration of Kan-GNPs by
measuring the OD at 600 nm every 3 hours for a period of 12 hours. MIC of Kan-GNPs
was found to be 24.46 µg/mL and 21.82 µg/mL against S. epidermidis and E. aerogenes
bacteria, respectively. (b and d) Visualizing the growth of S. epidermidis and E.
aerogenes bacteria on a solid agar plate in presence of MIC of Kan-GNPs obtained from
the growth assay. Untreated sample of bacteria was taken as control.
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To check the precision of the results, XTT, a cell viability assay was performed.
Viable or metabolically active cells have potential to convert the water-soluble XTT to a
water-soluble, orange colored formazan product which can be easily quantified
colorimetrically. The lowest concentration in the well which showed no orange color
formation or 90 % reduction in the absorption at 492 nm (characteristic for XTT) was
taken as the MIC. The MIC values of XTT assay for Gram-positive strain S. epidermidis
(Figure 6 (a and b)) and Gram-negative strain E. aerogenes (Figure 6 (c and d)) were in
compliance with the previous assays.
A comparison of results showed approximately two fold reduction in the MIC of
Kan-GNPs for all the bacterial strains tested when compared to the pure kanamycin
(Table 6). Therefore, kanamycin conjugated on to GNPs surface is more efficient in
combating the bacteria than the free antibiotic.
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Figure 6. Colorimetric illustration of dose dependent inhibition by Kan-GNPs against
Gram-positive, S. epidermidis (a, b) and Gram-negative E. aerogenes (c, d) bacteria. (a
and c) Susceptibility testing against varying concentrations of Kan-GNPs by
colorimetric assay which involves reduction of a yellow tetrazolium salt (XTT) to
orange formazan product by metabolic active bacterial cells. The MICs were similar to
the MIC obtained using growth assay and spread plate. (b and d) A plot corresponding to
XTT assay obtained by measuring absorbance of wells at 492 nm, which shows peak
absorption for orange formazan derivative. Wells with 90 % reduction in absorbance
compared to positive control or no orange color formation were taken as MIC.
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Table 6
Table 6. MIC100 of Kan and Kan-GNPs (µg/mL)
Kan Kan-GNPs Fold Change
Gram Positive
S. epidermidis 40
24.46
1.64
E. durans
100
35.23
2.85
Gram Negative
E. coli
60
25.06
2.39
E. aerogenes
40
21.82
1.83
Table 6. Illustration of MIC of Kan-GNPs against Gram-positive and Gram-negative
strains in comparison to pure kanamycin. The growth in presence of increasing
concentrations of Kan-GNPs was monitored by measuring the optical density (O.D) at
600 nm every 3 hours for a period of 12 hours to determine the MIC. Decrease in the
MIC of Kan-GNPs compared to pure kanamycin proved Kan-GNPs enhanced potential
in combating bacteria.
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Next we tested whether Kan-GNPs have greater efficacy than kanamycin against
kanamycin resistant and MDR bacteria. Two kanamycin resistant bacterial strains were
used, a genetically engineered Y. pestis kanamycin resistant strain (CO92::Km) and a
multidrug resistant P. aeruginosa clinical isolate (UNC-D). The MIC100 of kanamycin
against both of these strains is significantly higher than equivalent kanamycin sensitive
strains (WT Y. pestis CO92 and P. aeruginosa PA01; Table 7). When kanamycin
sensitive bacteria were incubated with Kan-GNPs a 2.88- and 7.50-fold decrease in
kanamycin concentration was required when bound to GNPs to inhibit the growth of Y.
pestis CO92 and P. aeruginosa PA01 respectively. In the case of the kanamycin
resistant and MDR bacterial strains, we observed even higher impact of GNPs on the
kanamycin MICs, with a 13.50- and 41.88-fold decrease in MICs for Y. pestis
CO92::Km and P. aeruginosa UNC-D, respectively. Importantly, GNPs linkage to
kanamycin resulted in kanamycin MICs similar to the kanamycin alone MICs of the
kanamycin sensitive strains. Taken together, our data demonstrate that GNPs linkage to
kanamycin reduces the kanamycin MIC against drug resistant strains.
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Table 7
Table 7. MIC100 of Kan and Kan-GNPs (µg/mLa)
Kan Kan-GNPs Fold Change
P. aeruginosa
PA01
50
6.67
7.5
b
UNC D-1 (MDR ) 139.46
3.33
41.88
Y. pestis
CO92
4.81
1.67
2.88
CO92::Km
180
13.33
13.5
a
Concentration of Kan
b
Multidrug resistant
Table 7. Illustration of MIC of Kan-GNPs against genetically engineered Y. pestis
kanamycin resistant strain (CO92::Km) and a multidrug resistant P. aeruginosa clinical
isolate (UNC-D). The growth in presence of increasing concentrations of Kan-GNPs
was monitored by measuring the optical density (OD) at 600 nm every 3 hours for a
period of 12 hours to determine the MIC. The MIC100 of kanamycin against both of
these strains is significantly higher than equivalent kanamycin sensitive strains (WT Y.
pestis CO92 and P. aeruginosa PA01; Table 7). When kanamycin sensitive bacteria
were incubated with Kan-GNPs a 2.88- and 7.50-fold decrease in kanamycin
concentration was required when bound to GNPs to inhibit the growth of Y. pestis CO92
and P. aeruginosa PA01, respectively. For kanamycin resistant strains, a higher impact
of GNPs on the kanamycin MICs, with a 13.50- and 41.88-fold decrease in MICs for Y.
pestis CO92::Km and P. aeruginosa UNC-D was observed respectively.
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3.3. Kan-GNPs treatment alters the morphology of bacteria
The morphology of Gram-positive (S. epidermidis) and Gram-negative (E.
aerogenes) bacteria against Kan-GNPs was determined by examining ultra-thin sections
of the samples under electron microscope (TEM), obtained using an ultra-microtome,
collected at various time intervals (0, 6 and 12 hours) of bacterial growth. A series of
morphological changes were observed for bacterial cells treated with nanoparticles.
Based on TEM observation, after 6 hours of incubation, Kan-GNPs were found to be
localized on the cell membrane, covering most of the surface of Gram-positive S.
epidermidis bacteria. Nanoparticles were also observed in the cytoplasm which shows
the ability of Kan-GNPs to permeate the bacterial cell wall. As a result of perforations
into the cell wall, disruption and leakage of cytoplasmic contents were observed after 12
hours resulting in complete cell lysis (Figure 7(a)). Cross-sectional TEM images showed
localization of Kan-GNPs on the surface as well as entry into the cytoplasm, suggesting
bactericidal action of Kan-GNPs resulting in the dual killing effect. A similar pattern of
lysis of bacterial cell wall by Kan-GNPs was observed against Gram-negative E.
aerogenes (Figure 7(b)).
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Figure 7. TEM images for visualizing the morphological changes in bacteria upon
treating with Kan-GNPs at different intervals of time. Panel (a) represents sequential
images (from left to right) of Gram positive, S. epidermidis bacteria treated with KanGNPs (24.46 µg mL-1) after 0 hour, 6 hours and 12 hours of incubation. Panel (b)
Represents sequential images (from left to right) of Gram negative, E. aerogenes
bacteria treated with Kan-GNPs (21.82 µg mL-1) after 0 hour, 6 hours and 12 hours of
incubation. After 6 hours of exposure, Kan-GNPs were found to adhere and penetrate
the bacterial cell wall which resulted in disruption of cellular environment leading to
lysis of cell due to leakage of cellular components as observed after 12 hours of
exposure.
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Permeability of Kan-GNPs into the bacterial cytoplasm is crucial for the delivery
of attached kanamycin to inhibit the bacterial protein synthesis. To assess the
permeability of Kan-GNPs, fluorescence imaging using propidium iodide (PI) was used.
PI dye which shows fluorescence after binding to nucleic acids in membrane
compromised cells, was used to detect dead cells. Kan-GNPs treated samples of S.
epidermidis (24.46 µg mL-1) and E. aerogenes (21.82 µg mL-1), after incubating for 12
hours at 37 °C were stained with PI dye followed by further incubation in the dark for 2
hours (Figure 8(a)). Fluorescence images of the samples showed 75 ± 10% permeability
of Kan-GNPs for S. epidermidis and E. aerogenes respectively when compared to
control which showed only 15 ± 10% permeability for S. epidermidis and E. aerogenes
respectively (Figure 8(b)).
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Figure 8. Fluorescence images of Kan-GNPs induced cell membrane permeability using
propidium iodide (PI) dye which has strong binding affinity towards nucleic acids.
Upper panel represents Gram-positive, S. epidermidis and lower panel represents Gramnegative, E. aerogenes. (a) The image represents differential interference contrast mode
with corresponding fluorescence image. Untreated samples of respective bacteria
without Kan-GNPs were taken as control. (b) Represents a plot showing percentage
permeability of S. epidermidis and E. aerogenes bacterial cells in presence (MIC) and
absence (control) of Kan-GNPs.
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These results supported the observation from TEM cross-section images
confirming bactericidal action of Kan-GNPs resulting in lysis of bacterial cell. KanGNPs binds to the surface of the bacterial cell wall, making perforations which disrupts
cellular equilibrium. In addition, free kanamycin existing on GNPs surface may also
bind to the 30S ribosome and inhibit protein synthesis, thereby retaining its inherent
pharmacological activity.70 We also hypothesize that due to the presence of amine
groups in kanamycin, which can easily be protonated (RNH2 + H2O  RNH3+)
imparting a partial positive charge to the Kan-GNPs, could bind to the negatively
charged DNA (due to presence of phosphate) and unwind the two strands, resulting in
disruption in DNA.62 The positive amine groups could also facilitate in binding with the
negatively charged bacterial cell wall as observed from the TEM pictures.71,72
Correlating the hypothetical antibacterial mechanism of Au@TiO2 systems,73 Kan-GNPs
present on the surface of bacteria could also extract electrons from the bacterial
respiratory proteins, thereby starving bacteria to death. In addition, the internalized KanGNPs could affect important biological processes in bacteria such as ATP synthesis,
protein synthesis and many more.74 As a result of multiple routes of bactericidal action,
it becomes relatively problematic for the bacteria to resist the action of antibiotic GNPs,
thereby making them more favorable for clinical use as an effective antibacterial agent.
One of the major concerns regarding the use of GNPs for clinical applications is its
cytotoxicity which is still under debate. In a previous study, spherical gold nanoparticles
(20 ± 5 nm) were shown to be nontoxic75 which can be used to predict the nontoxicity of
Kan-GNPs.
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4. CONCLUSION
Our results illustrates a novel and efficient antibacterial strategy involving the
use of a commercial antibiotic, kanamycin capped onto the surface of gold nanoparticles
through a single-step process without the use of any toxic chemicals. Monodisperse,
spherical GNPs in the size range of 20 ± 5 nm were formulated which showed dosedependent bactericidal activity against both Gram-positive and Gram-negative bacteria.
Significant decrease in the MIC of Kan-GNPs in comparison to pure kanamycin proved
Kan-GNPs enhanced potential in combating Kan-resistant and MDR bacteria. KanGNPs were found to kill bacteria by causing perforations in the bacterial cell wall, as
well as probably due to the protein inhibition activity of free kanamycin on the surface,
causing loss of cellular integrity leading to leakage of cell constituents, which eventually
resulted in lysis of the bacterial cell. In conclusion, we report a simple, bio-friendly
process using combined reducing and capping ability of kanamycin to produce stable
and efficient GNPs which holds a promising future for its clinical use as a potent
antibacterial agent against multi drug resistant bacteria. This could facilitate biomedical
application of Kan-GNPs and can open a new route for other commercially available
antibiotics to which bacteria have gained resistance.
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5. FUTURE STUDIES
In vivo interation of Kan-GNPs in animal model
In order to use a nanoformulation for biological applications, the Kan-GNPs
should be tested for in vivo activity in experimental animal models. This will be done by
studying the physiological changes occuring in animal system upon acute and chronic
exposure to Kan-GNPs.76 The MIC concentration of Kan-GNPs will be administered
intravenously to the experimental animal model and animals will be studied for various
parameters such as change in body temperature, body weight and behaviour before and
after treatment with Kan-GNPs.76 The blood and urine samples will be collected at
specific time intervals and tested for hematological and urinary analysis. For detailed
interaction studies, serum biochemical and histo-pathological analysis will also be
done.76 All the toxicity analysis will be done for Kan-GNPs and will be compared with
pure kanamycin.
Pharmacokinetic (PK) and pharmacodynamic (PD) studies of Kan-GNPs
After succesful quantitative analysis of Kan-GNPs for in vivo applications, we
will study the the Absorption Distribution Metabolism Excretion (ADME) profile of
kanamycin nanoformulation which will give us pharmacokinetic information, whereas
efficacy and toxicity studies in pre-clinical models will provide us pharmacodynamic
information of Kan-GNPs.77 The ADME, PK and PD studies of Kan-GNPs will be done
by collecting samples from blood, tissues, plasma, bile and urine upon treating animal
model with Kan-GNPs and will be tested for drug concentration, half life, clearance,
toxicity and release profile of drug.77
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7. APPENDIX
7.1. Appendix A: Product specification of kanamycin sulfate, Streptomyces
kanamyceticus

Figure 9. Illustrates structure of kanamycin sulfate. a) Represents chemical structure
of kanamycin sulfate. b) Represents molecular model of kanamycin sulfate
constructed using Gausview 5.0.
Product Name: Kanamycin sulfate, Streptomyces kanamyceticus
Chemical Formula: C18H36N4O11. H2SO4
Formula Weight: 582.6 g/mole
Description: White odorless crystalline powder
Solubility: Soluble in water (10 mg/mL)
Turbidity: Clear
Storage: 15 – 30 °C
Supplier: EMD Millipore
Specifications: Contains more than 98 % kanamycin
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7.2. Appendix B: Thermo gravimetric analysis protocols of Kan-GNPs
Method log (Nitrogen atmosphere)

Figure 10. Represents method for thermal degradation of KanGNPs in presence of nitrogen as purge gas.
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Method log (Air atmosphere)

Figure 11. Represents method for thermal degradation of Kan-GNPs in
presence of air as purge gas. In this method, air was selected as purge gas
for complete sample run in order to determine percent weight loss of KanGNPs upon complete oxidation.

58

7.3. Appendix C: Thermo gravimetric analysis of Kan-GNPs using air as purge gas

Figure 12. Represents thermal degradation plot showing weight loss of organic
material for kanamycin (----) and Kan-GNPs (- - -) respectively using air as
purge gas. The samples were heated from room temperature till 850 °C using
air as purge gas in order to facilitate complete oxidation of organic compound.
Kan-GNPs showed weight loss of 35.05 % which is comparable to percent
weight loss of Kan-GNPs obtained using nitrogen as purge gas.
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7.4. Appendix D: Microtiter plate schematic for growth curve assay and XTT assay

Figure 13. Represents design of 96 wells microtiter plate. All sample reactions were
done in triplicate. Sample row contained varying concentration of Kan-GNPs
concentrated to 100 µL as final volume, 140 µL nutrient media and 10 µL of bacterial
culture (1 x 106 CFU per mL). Blank wells contains same concentrations of drug as in
sample rows and 150 µL nutrient media. Control wells contained 100 µL sterilized
nanopure water, 140 µL nutrient media and 10 µL of bacterial culture. For XTT assay,
50 µL of XTT solution (previously activated with menadione) was added to each
sample, blank and control wells.
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